Judge tosses decade-old investor suit against Pfizer and Celebrex weeks before trial

Eric Palmer A long-running and often contentious securities lawsuit tied to Pfizer's vilified pain drugs Celebrex and Bextra was set for a September trial, ...

UPDATED: FDA gives an early OK to lymphoma drug Beleodaq

John Carroll Spectrum Pharmaceuticals has won an early nod from the FDA for belinostat, a new T-cell lymphoma drug that will be sold as Beleodaq. FierceBiotech News

Another Pfizer bid for AstraZeneca? Investors weigh in

Stacy Lawrence A higher price could get a deal done between Pfizer and AstraZeneca if British regulators play along, but investors aren't convinced that would be a particularly ...

With Shire takeover bid, AbbVie looks to succeed where Pfizer failed

Carly Helfand AbbVie may be working with some of the same advisers who worked on Pfizer's so-far-failed play for AstraZeneca. But after three rejections from target Shire–the ...

FDA will hear Sanofi’s second plea for Lemtrada approval

Emily Wasserman On Friday, the FDA accepted Sanofi's supplemental application for its once-rejected multiple sclerosis treatment Lemtrada for consideration, and a 6-month review ...

Chase banks $21M round for Alzheimer’s drug research

John Carroll Promising to use its technology to enhance the efficacy and safety of currently approved Alzheimer's drugs, Chase Pharmaceuticals says it has now added $ 21 million ...

Reckitt Benckiser gives up on Merck OTC deal, leaving Bayer open shot

Eric Palmer British consumer goods giant Reckitt Benckiser indicated Wednesday that bidding for the consumer healthcare unit of Merck had gotten out of hand, and so it decided to step ...

Sources: Bayer offers animal health biz, cash for Merck’s OTC unit

Eric Palmer When bidding wars get hot, that often springs information leaks. The latest is that there is some swap-and-shop haggling going on between Bayer and Merck over Merck's ...

AbbVie’s Humira turns in 18% surge in sales

Eric Palmer AbbVie's Humira is the gift that just keeps on giving, and it presented the still-young drugmaker with a very big boost in the first quarter, powering its sales and ...

Biogen revenue leaps 50% on blockbuster-level Tecfidera sales

Tracy Staton Launched last April, Tecfidera racked up more than a half-billion dollars in sales for the first quarter of this year. That puts its cumulative total at $ 1.38 billion–well ...

Valeant touts quick cost cuts in $45B hostile bid for Allergan

Carly Helfand As The Wall Street Journal reports, the Irvine, CA-based Allergan is the latest apple of deal-happy Valeant's eye. And allied with activist investor Bill Ackman–who ...

Novartis slashing thousands more jobs in global reorganization, shifting many to India

Tracy Staton Novartis' 500 Swiss job cuts announced earlier this month are just the tip of a global iceberg. The company plans to cut or shuffle up to 4,000 jobs in its pharma business, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS